awmsg logo



dextromethorphan/quinidine (Nuedexta®)


Reference No. 1582

Publication date:
03/12/2013


Appraisal information

dextromethorphan/quinidine (Nuedexta®) 15 mg/9 mg capsule
dextromethorphan/quinidine (Nuedexta®) 23 mg/9 mg capsule


Company: Jenson Pharmaceutical Services Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Marketing authorisation withdrawn
Advice No: Not available
Ratification by Welsh Government: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

LICENCE WITHDRAWN. Please refer to the European Medicines Agency website for further information. In the absence of a submission from the holder of the marketing authorisation, dextromethorphan/quinidine (Nuedexta®) cannot be endorsed for use within NHS Wales for the symptomatic treatment of pseudobulbar affect in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.
Statement of Advice (SOA)
Download